Disc Medicine Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Disc Medicine Inc 's ROA in the second quarter of 2026?
Disc Medicine Inc recorded a cumulative net loss of $-246 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -27.77%.

However, within the Healthcare sector 445 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3701, from total ROA ranking in the first quarter of 2026 at 4279.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	103.6 %	5.77 %	62.42 %	27.32 %	30.35 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-246	-242	-212	-181	-145
Return On Assets (TTM)	-27.77 %	-33.88 %	-30.19 %	-28.96 %	-24.58 %
IRON's Total Ranking	# 3701	# 4279	# 3741	# 3675	# 3645
Total Assets (TTM) in million	1,354	750	807	630	665
Seq. Total Assets Change	80.49 %	-7.02 %	28 %	-5.21 %	-6.23 %
Seq. Net Income Change	-	-	-	-	-

IRON's 5 Years Annual ROA >> Back to IRON Management Effectiveness >> Compare IRON ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 172
Sector	# 446
Overall	# 3665

Return On Assets Statistics
High	Average	Low
-21.07 %	-32.4 %	-48.99 %
(Mar 31 2025)		(Sep 30 2022)

Financial Statements
Disc Medicine Inc 's Assets	$ 1,354 million	IRON's Balance sheet
Disc Medicine Inc 's Income	$ -60 million	Quarterly IRON's Income Statement
IRON's Income by Division		See IRON's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	62.42 %	35.05 %	83.73 %	42.56 %	1144.08 %
Total Assets in million	807	497	368	200	140
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-212	-109	-76	-47	-72
Annual Return On Assets	-26.3 %	-22.01 %	-20.78 %	-23.39 %	-51.18 %

IRON's 5 Years Annual ROA >> Back to IRON Management Effectiveness >> Compare IRON ROA to its Competitors

More Return On Assets Ratios
IRON's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IRON's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IRON's Competitors
Subscribers only: Roa for Disc Medicine Inc 's Suppliers
Subscribers only: Return On Assets for IRON's Customers

You may also want to know
IRON's Roi	IRON's Inventory Turnover Ratio	IRON's Growth Rates	IRON's Dividend Comparisons
	IRON's Profitability Ratios	IRON's Asset Turnover Ratio	IRON's Dividend Growth
IRON's Roe	IRON's Valuation Ratios	IRON's Financial Strength Ratios	IRON's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-14T03:54:56+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.